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Abstract. This review paper attempts to provide an overview in the fabrication and application of
organic–inorganic based composites in the ﬁeld of local drug delivery for bone. The concept of local drug
delivery exists for a few decades. However, local drug delivery in bone and specially application of
composites for delivery of drugs to bone is an area for potential research interest in the recent time. The
advantages attained by an organic–inorganic composite when compared to its individual components
include their ability to release drug, adopting to the natural environment and supporting local area until
complete bone regeneration, which make them carriers of interest for local drug delivery for bone.
KEY WORDS: biomaterials; carrier systems; composite; local delivery; organic–inorganic.
INTRODUCTION
Steady increase in geriatric population, changes in
lifestyle, and adverse effects of modernization have contrib-
uted to steep increase in the number of orthopedic patients in
recent years. Over 1.5 million osteoporotic fractures are
reported annually in the USA alone, costing approximately
$15 billion each year (1), and an estimated 60 million people
will be disabled or injured in developing countries in the next
10 years (2). About 50,000 hip replacements (and as many
knees) are performed every year in the UK, and 193,000 are
performed in the USA for osteoarthritis (3). Infective
complications occur in 2–6% of patients following prosthetic
joint replacement of the hip (4) and 0.7–9% following knee
arthroplasty (5–7). In parallel, also the number of medica-
tions to treat and even prevent these diseases has expanded
signiﬁcantly in recent years (8). However, success in therapy
has not been overwhelming as with other disease conditions.
Key issues for failure include the inability to maximize drug
access to bone and maintain optimum drug concentration for
prolonged periods of time. To alleviate the drawbacks of
conventional therapy, local drug delivery to bone had been
tried by modern medicine from the 1970s (9). However, it is
from the year 2000 that research on local delivery of drug to
bone has gained considerable attention (Table I). Note that
the numbers of publications in the last 3 years are double and
decuple the number published in earlier decades.
Bone substitutes as acrylic polymers, biodegradable
polymers, and ceramics are popular choices for carriers to
bone drug delivery, and reviews based on them do exist (10–
12). However, expectations of these implants to exhibit
bioactivity and favor tissue regeneration in addition to
controlled drug delivery could hardly be achieved with either
class of bone substitutes. On the other hand, implants based
on composites (organic–inorganic) of bone substitutes are
able to meet the expectations (13–15). Widespread applica-
tion of composites exists in the ﬁelds as construction
engineering, polymeric research, etc. However, application
of composites for the fabrication of drug delivery devices that
can be placed in the bone is still in its infancy. This review is
based only on those articles that have applied organic
(polymer)–inorganic [inorganic chemicals, bioactive glass
(BG), and bioceramics] composites for bone drug delivery.
The purpose of this article is to provide an overview about
the role of organic–inorganic composites for local drug
delivery in bone, their fabrication, and important properties
to be considered on development of the same. A review
based on organic–inorganic composites for drug delivery to
bone locally does not exist, at least to our knowledge.
However, this article is not encyclopedic; rather, select
examples have been chosen to summarize the progress.
NEED FOR COMPOSITES
Most natural materials are composites made up of both
inorganic and organic components organized in complex
structures. Bone is a composite matrix of collagen (organic)
strengthened with hydroxyapatite (Hap) (inorganic). Within
and around the composite matrix are located the bone cells,
namely, osteoblasts, osteocytes, osteoclasts, and osteoproge-
nitor cells.
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Various materials from stable or degradable polymers to
inorganics, including glass and ceramics, have been notably
tried for local drug delivery in bone. The carrier materials
selected for drug delivery in bone are expected to be
affordable, exhibit predictable release characteristics,
mechanically and biologically compatible with local bone
tissue, and possibly bioactive, bioresorbable, and osteocon-
ductive/osteoinductive. While bioactive materials (e.g., BG)
bonds physically and chemically to bone, a bioresorbable
material [e.g., calcium sulfate (CS)] is resorbed slowly, ideally
substituted by new bone formation. In addition, while
osteoconductive materials [e.g., tricalcium phosphate (TCP)]
are suitable for bone cells to attach, grow, multiply, and
spread, osteoinductive materials (e.g. Hap) are capable of
stimulating primitive stem cells or immature bone cells to
grow and mature. Although each carrier material shall exhibit
remarkable advantage over others, non-degradability and
compulsion for a second surgery on healing site to remove the
stable polymers, high cost, impaired osteoconduction, and
adverse tissue response of biodegradable polymers, unsuit-
ability of glass for load bearing regions of bone, and lack of
ductility and poor degradability with ceramics are signiﬁcant
limitations to overcome (16–19). Hence, the option for an
organic–inorganic composite material would be more rational
than individual categories of carrier materials. Comprised of
multiple phases mixed to provide better performance, com-
posites are expected to provide desired mechanical stability,
improve tissue integration, and retard drug release better.
Table II presents a representative list of studies published
based on organic–inorganic composites as drug delivery
systems for bone. Figure 1 depicts some possible combina-
tions in the formation of organic–inorganic composites for
bone drug delivery.
BONE, DRUGS, AND LOCAL DELIVERY
Bones are rigid organs serving various vital functions in
the body. In addition to providing shape, aiding in movement,
and providing protection for vital inner organs, they are the
production house of blood cells, storage house of fat, mineral,
and growth factors, and play considerable role in detoxiﬁca-
tion and acid–base balance of blood. However, bone in
general is a poorly perfused organ. During pathological
conditions, the blood supply in the local area gets further
hampered, making the availability of drug rather question-
able. Although parenteral route is expected to provide better
bioavailability and avoid the possibility of hepatic ﬁrst pass
metabolism as compared with oral route, bone being a poorly
perfused organ is the major reason for experiencing poor
supply of drugs at the site of treatment. Hence, the need to
administer drugs at high doses and for prolonged periods, in
conventional therapy, would appear logical. For example
ceftriaxone should be administered at 2 g a day by i.v. for 4–
6 weeks in the treatment of bone infections (41) and
bisphosphonates as Risedronate at 5 mg per day orally at
least for 6 months in case of osteoporosis (42). From the drug
point, delivering large amounts of drugs to the body may
display an increase in bioavailability but could result with
exorbitant irrational quantities of drug getting eliminated
from the body with potential increase in undesired serious
side effects as nephrotoxicity and hepatotoxicity and esca-
lated treatment cost, as with antimicrobials (43). In certain
cases of drugs as growth factors, even a high dose of growth
factors injected directly as an aqueous solution might struggle
to maintain the desired biologic effects in vivo because of in
vivo metabolism and enzymatic digestion resulting in short
half-life of the drug in the body (28,44). Local delivery of
drugs offer various possibilities for avoiding serious side
effects, avoiding infusions, decreased hospitalization, reduced
medical expenses, release drug in a sustained fashion,
maintain high drug concentrations locally, reduce presence
of drug in systemic blood circulation, maintain drug stability
for a longer period, etc. Therefore, it becomes indispensable
to seek local release of drugs for improved efﬁcacy and faster
healing.
Antibiotics
Of the various categories of drugs researched for local
delivery in bone, antibiotics occupy a major section. Normal
bone is highly resistant to infection, which can only develop
as a result of trauma, very large inocula, or due to the
presence of foreign bodies. Irrespective of the advancement
in making surgeries and prosthesis, available sterile, and
achieving aseptic conditions in operation theatres, infection
associated with major surgeries are still unavoidable. Due to
their application for prophylaxis and therapeutics antibiotics
need to be applied to bone in every case of surgery, in
addition to cases of bone infections. When the microbial load
has crossed a critical density, they form bioﬁlms that are quite
hard for antibiotics to penetrate, often resulting in relapse of
infection (45). Very high concentrations of antibiotics are
required to eradicate them, which could hardly be attained by
conventional routes of delivery without serious side effects.
Antibiotics in general are hydrophilic drugs, hardly
exhibit stability problems (except a few as cephalosporins)
making them suitable to load with any kind of composite.
Release of antibiotic shall depend on various factors. How-
ever, insufﬁcient release of antibiotics on the basis of time and
concentration could lead to development of resistant strains
and growth of microorganisms on the surface of the scaffolds.
Growth Factors
Although bone has the capability of self-regenerating or
remodeling to a certain extent, the process is rather slow.
Before operating bone, a question more frequented would be
how fast it would be healed. It is estimated that delayed or
impaired healing will occur in 5–10% of the 5.6 million
fractures that occur annually in the USA, and up to 10% of
all fractures will require additional surgical procedures for
impaired healing (46). Delayed bone healing leads to socio-
Table I. A List Indicating the Number of Publications on Local
Delivery to Bone as Indexed in PubMed
Years Number of publications
2006–2008 63
2000–2005 73
1990–1999 34
1980–1989 06
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economic costs of up to 14.7 billion Euros per year in Europe
alone (47). Bone healing is a slow and complex physiological
process initiated and controlled by growth factors and the
healing potential inﬂuenced by a variety of biochemical,
biomechanical, cellular, hormonal, and pathological mecha-
nisms. Osteoinductive factors as growth factors [e.g., bone
morphogenetic proteins (BMP), insulin-like growth factors,
and transforming growth factors (TGF)] stimulate bone
regeneration and repair bone faster. Just introduction of
these proteins do not produce expected results, as they diffuse
faster. Hence, controlled delivery of growth factors and an
environment that is osteoinductive/osteoconductive could be
expected to provide better bone growth.
Others
Other classes of drugs as anti-inﬂammatory (38,39),
anticancer (37), and hormones (40) have been tried with
success for the local delivery to bone with composites.
Nonsteroidal anti-inﬂammatory drugs have widespread appli-
cation in orthopedics to inhibit heterotopic ossiﬁcation and
control postoperative pain, inﬂammatory arthritis, and osteo-
arthritis. Applications of nonsteroidal anti-inﬂammatory
drugs, such as ibuprofen and aspirin, for local delivery with
composites have been reported with success (38,39). Deﬁ-
ciencies of systemic hormone, e.g., estrogen, quite common in
women after menopause, signiﬁcantly alter the strength of the
bone. Low estrogen levels are the major cause for osteopo-
rosis that results in brittle bones, highly susceptible to
fracture. As the local area would already be brittle, placing
a composite that could also support the area in addition to
delivering estrogen for prolonged periods would be the
rational approach. Osteosarcoma is the most common type
of bone tumor, and bone is frequently the ﬁrst site and the
only site of breast cancer at recurrence (37). Cancer demands
local delivery and for prolonged periods. Most osteosarcomas
are treated with surgery followed by chemotherapy. With
composites ﬁlling the bone void and supporting the local area
with anticancer drugs like paclitaxtel released locally for
prolonged periods could move cancer therapy a step forward.
FABRICATION
Fabrications are aimed to satisfy two requirements.
1. Fabrication of suitable scaffold for bone regeneration/
support and
2. Incorporation and subsequent release of drug in a
predestined schedule
With numerous choices of materials to play with,
composite materials widen the choices for design of drug
delivery system. Composites could be fabricated by:
1. Organic and inorganic components mixed directly and
processed to form composite (21,26,28,32)
Fig. 1. Some possible combinations in the formation of organic–inorganic composite
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2. Preformed structures such as microspheres/beads/
blocks made with either of the composite components
mixed with the other to form a matrix composite
(24,48)
3. Organic or inorganic preformed structures coated with
composite materials (15,29).
The structures are prepared by various techniques and
are designed to be nonporous (21,24,26) or porous (20,22,23).
These varied choices in forming a composite bring with
consideration for several parameters (e.g., components com-
position, bioactivity, osteoconductivity, osteoinductivity, resorb-
ability, drug releasability, mechanical property, stability etc.)
during design and fabrication of drug delivery systems.
Drugs can be loaded by:
1. Direct mixing with the basic components and then
processed to form composite structures (33,36,39,49–
51)
2. Entrapping with one of the basic components (as
formation of microspheres) and then adding to other
components for processing (24,48,52–55)
3. Mixing with a solution of polymer or composite and
coating it to preformed structures made of one of the
components (15,20,29)
4. Impregnating or adsorbing on preformed structures
(27,30,31,56)
Of the methods stated, drugs that are loaded by
impregnation or adsorption to preformed structures (27,56)
in general exhibit a greater burst release than other methods.
Drugs that are entrapped in one of the basic components of
the composite (e.g., in polymeric microspheres) (52,53)
exhibit lesser tendency for burst release, due to their
accessibility limitations to release medium. Schnieders et al.
reported that burst releases of drug exhibited by polymeric
microspheres were not observed with composites (24).
Compression
Compression is the simplest technique in fabrication. In
the fabrication of organic–inorganic composite systems, raw,
preformed (microspheres) (24), or pretreated (coagulated/
precipitated) materials (28) are mixed and compressed with
(24) or without (28) the application of heat. Compressed
structures made by a single phase of material can be coated
with the other phase to form a composite (20).
Castro et al. prepared composite by simple mixing and
compression (57). PLA, phosphates (Hap/TCP), and drug
were mixed and pressed in carver hydraulic press at 520 or
312 MPa for 5 min. Although such fabrications would release
drug for prolonged periods, the effect of compression force
on drug release would be signiﬁcant. The authors reported
that the higher the compression force, the slower the release
of the drug.
Kim et al. prepared phosphate glass–PCL composites via
solvent extraction and thermal pressing techniques (28). PCL
and drug solution in dimethyl carbonate (DMC) was added
with phosphate glass dispersion in DMC containing drug and
mixed well. The mixture was added to absolute ethanol and
stirred vigorously to extract the solvent. The coagulated
samples were dried and ﬁnally pressed under a load of
100 kg at 80°C. Compared to PCL, glass–PCL composites
exhibited enhanced degradation and controlled drug release
due to high capacity water uptake and different dissolution
rates of glasses depending on the composition.
Schnieders et al. prepared calcium phosphate–polylac-
tide-co-glycolide (PLGA) composite bone cement by com-
pressing preformed organic phase with inorganics (24). Drug-
loaded PLGA microspheres were prepared by spray-drying
process. The microspheres were then incorporated into
apatitic cement matrix made from tetracalcium phosphate
and dicalcium phosphate anhydrate and biaxially compressed
at 2.7 MPa for 5 s, followed by a load of 700 kPa for 2 h at 37°C
to result composite cylinders. However, the addition of drug-
loaded microspheres into apatitic cement and pressing inﬂuence
a range of properties as drug release, compressive strength and
setting time.
Miyai et al. 2008 prepared composite discs similarly with
β-TCP and polycaprolactone (PCL) by compression molding
and coating (20). Porous β-TCP discs were prepared by a
solvent-free process in which no toxic solvent was used. β-
TCP slurry was poured on a network of stainless steel needles
and subjected to a pressure of 28 MPa. After compression
molding and drying, the compacts were sintered (1,100°C for
1 h) and ﬁnally dipped in molten PCL-containing drug.
Coating inorganic scaffolds with organic substrates containing
drug inﬂuences the mechanical property of the scaffold and
the drug release proﬁle.
Melt Compounding
Melt compounding is another popular technique in
fabrication. Organic and inorganic components of the com-
posite are mixed with the drug, melted, and formed into
shapes on cooling. Koort et al. (49) and Makinen et al. (26)
prepared composites containing ciproﬂoxacin in a BG-
biodegradable matrix. While PDLLA was applied by the
former, the latter had PLGA. Fixing a melting temperature
could be one crucial step. Although the temperature shall be
chosen below the degradation temperature of the drug, a low
temperature could cause uneven distribution of the drug in
the composite due to incomplete melting of polymer and high
viscosity. On the other hand higher temperature could
degrade the drug as there could be some phase trans-
formation or complex formation on getting mixed with the
components of the composite. A differential scanning calo-
rimetry of the compound to be melted shall help to alleviate
the problems.
Cross-Linking/Clotting/Polymerization
Cross-linking is the process of chemically joining two or
more molecules by covalent or ionic bonds. Yaylaoglu et al.
cross-linked composite membranes prepared by solvent
casting (58). A mixture of gelatin, drug (gentamicin), calcium
phosphate, and water were warmed for an hour, vortexed,
and poured in a Petri plate to form a membrane on cooling.
Rectangular pieces were cut and cross-linked with glutaral-
dehyde solution. During cross-linking substantial decrease in
drug content could occur due to the leaching of drug.
However, leaching was reduced by creating higher diffusional
restrictions as increasing the concentration of polymer.
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Kelpke et al. prepared composites by clotting (59).
Human ﬁbrinogen and varying amounts of bovine-derived
Hap were mixed with recombinant ﬁbroblast growth factor
and clotting achieved by the addition of human thrombin.
Fibrin and ﬁbrinogen degradation products function as a
scaffold for migrating ﬁbroblasts, stimulate soft tissue cell
growth, accelerate vascular sprouting, induce growth factor
release from responding cells, and hence suitable as a
biodegradable delivery system for various growth factors.
Fibroblast growth factors undergo thermal degradation at 37°C,
resulting to a short biological half-life in vitro. Kelpke et al.
reported that ﬁbroblast growth factor was protected against
thermal degradation and inactivity by clotting.
Composites prepared by polymerization are quite
often those containing PMMA. Composites containing
alumina, drug, PLA, and PMMA were prepared by free
radical polymerization with benzoyl peroxide as initiator
(60). Due to their mutual interaction through polar
coupling and hydrogen bonding, there exists good adhesion
between alumina–polymer associates. Composites contain-
ing a mixture of polymer, glass, and drug by free radical
polymerization were prepared by Ragel et al. (33). In
short, methyl methacrylate/benzoyl peroxide solution was
added to polymethylmethacrylate (PMMA). PLA followed
by glass premixed with drug was added and formed into
parallelepipeds by forcing the mixture into Teﬂon molds
and dried at 60°C for 24 h. Padilla et al. (50) prepared
composites in a similar procedure with Hap, gentamicin,
PMMA, and poly(ethyl methacrylate). Composite micro-
spheres by dispersion polymerization technique containing
coralline Hap and gelatin were prepared by Sivakumar et
al. (31). A mixture containing coralline Hap and gelatin
solution was added drop by drop into PMMA dispersion
solution with constant stirring, resulting to the formation of
microspheres. Glutaraldehyde saturated toluene was added
as cross-linking agent. After cross-linking, PMMA was
washed out by several installments of solvents with
toluene, acetone, and ﬁnally water. Loading of drug was
performed by immersing the composite microspheres in
phosphate-buffered saline containing drug.
Drug can be loaded either with the raw materials before
polymerization or after formation of composites. However,
stability of the drug should be considered as rise in temper-
ature during polymerization of PMMA reportedly range from
80°C to 124°C (61,62). In addition to the processing
conditions, components of the composite themselves may
inﬂuence drug properties. For example, ibuprofen shifts from
amorphous to crystalline state due to the presence of α-Al2O3
together with PLA, resulting in faster release (60).
Emulsion–Solvent Evaporation Method
Preparation of polymeric microspheres by emulsion–
solvent evaporation method is a popular technique. Oil phase
(usually an organic solution of polymer) is dispersed in an
aqueous phase containing an emulsiﬁer and the dispersion
stirred or ultrasonicated for prolonged periods for evapora-
tion of organic solvent and formation of microspheres. In
such a technique, the addition of inorganic phase with the
organic phase will result in the formation of composite
microspheres. Li et al. (27) prepared organic–inorganic
composite microspheres by this method. Wollastonite pow-
ders were mixed with organic solution of PHBV and the
mixture stirred for 2 h to gain a homogeneous mixture. The
PHBV/wollastonite mixture was then added dropwise into
1% polyvinyl alcohol solution. The mixture was vigorously
stirred for 24 h to allow complete solvent evaporation. The
resulting microspheres were washed twice with deionized
water and then collected by ﬁltering. After that, these
microspheres were lyophilized to dry. Drug loading was
performed by adsorption technique by immersing the micro-
spheres in drug solution for 24 h. A modiﬁed version was
employed by Wang et al. (54). Drug-loaded Hap nano-
particles were dispersed in an organic solution of PHBV and
polyethylene glycol (PEG) by ball milling. The resulting
mixture was added into water with methyl cellulose as
emulsiﬁer and the resulting emulsion stirred for few hours
to evaporate the organic solvent. The collected microspheres
were ﬁnally freeze-dried. The addition of PEG could improve
the permeability of the polymer and surface property of
microspheres.
In addition to the simple emulsion–solvent evaporation
process, composites can also be prepared by multiple (w/o/w)
emulsion–solvent evaporation (55). Hap powder and drug
(BSA) were dispersed in phosphate-buffered saline (PBS)
buffer to form the ﬁrst water phase. PLGA in an organic
solvent served as the oil phase. The ﬁrst water phase and oil
phase were mixed at 1,000 rpm to form w/o simple emulsion.
The ﬁrst emulsion was added to an aqueous solution of PVA
and stirred at 500 rpm for a few hours to form a multiple
emulsion (w/o/w) and drive off organic solvent and solidify
the microspheres. The microspheres were collected and
ﬁnally freeze-dried. As compared to the earlier examples
stated here, drug could be added initially in this case.
However, the ﬁnal drug amount present would heavily
depend on the encapsulation efﬁciency of the process. In
addition, the release of drug from these microspheres would
depend on the rate of polymer degradation in addition to
drug diffusion through pores of microspheres.
Freeze Drying
Freeze drying or lyophilisation is a drying technique that
freezes the solvent present in the material and sublimes it,
resulting to a material subjected to less damage as compared
to other drying processes, which usually employ high temper-
atures. Hence, freeze drying could be a better option when
the process involves thermolabile materials as enzymes,
proteins, etc. In addition, freeze drying does not usually cause
shrinking or toughening of the material and results with a
microporous structure. Drug can be incorporated either
during homogenization step (63) or by adsorption (14,30)
technique before (14) or after (23,30) freeze drying.
Martins et al. (63) homogenized Hap and anionic
collagen. Drug was added to the composite mass and
lyophilized. Zhang and Zhang (30) applied a similar proce-
dure with invert calcium phosphate and β-TCP as inorganic
phase and chitosan as organic phase. However, drug loading
was done by adsorption technique with lyophilized sections of
the composite. Lee et al. (14) prepared composite micro-
granules with chitosan and TCP. TCP was added to chitosan
solution and added dropwise into a coagulation solution of a
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4% NaOH ethanol/water mixture. The resultant microgra-
nules were washed and freeze-dried. TGF was incorporated
by adding the composite microgranules into a solution of
TGF-β1 and stored overnight at 4°C before freeze-drying.
Zhang et al. reported the preparation of composite scaffold by
freeze-drying (64). Invert calcium phosphate glass and Hap
powders were mixed into chitosan solution to make a
composite mixture. The resultant mixture was frozen and
freeze-dried for 4 days to obtain composite scaffolds. By a
similar procedure, Gravel et al. (65) prepared chitosan–
coralline powder composite. Although systems obtained by
freeze-drying technique are porous, additional porosity as
needed can be obtained by salt-leaching technique (23).
Zhang et al. (23) prepared PDLLA/biphasic calcium
phosphate scaffolds by salt-leaching technique. PDLLA
was added to biphasic calcium phosphate dispersed in 1,4
dioxane–water solvent and mixed to result a gel. Ammo-
nium bicarbonate salt particles were added to the gel, cast
and freeze-dried. The resultant products were immersed in
distilled water to leach out the salt and dipped in PEG–
drug mixtures.
Freeze Gelation
Freeze gelation method can be used to prepare highly
porous scaffolds without using the time and energy
consuming freeze-drying process. The porous structure
was generated during the freeze of a polymer solution,
following which the polymer was gelled under freezing
condition so that the porous structure would not be
destructed during the subsequent drying stage (66). Hsieh
et al. (44) reported preparation of chitosan/γ-PGA solution
by freeze gelation process. In this method, the frozen
scaffold solution (chitosan/γ-PGA) was immersed in a
gelation solution (3 M NaOH/ethanol solution) at a
temperature lower than its freezing point (−20°C). The
scaffold had already gelled before the drying stage; thus,
the porous structure could also be retained without
lyophilization by this method. Hsieh et al. (44) also
reported that the freeze-gelled composites exhibited a
better proﬁle for rhBMP-2 as compared to freeze-dried
scaffolds. Although this process has been compared to
freeze drying, it is a form of sol–gel processing that enables
ceramic fabrication without the need for high temperature
sintering.
Sol–gel
There is considerable interest in organic–inorganic
hybrid composite materials prepared via sol–gel process.
First, a homogeneous sol is prepared, which transforms to
a gel, followed by controlled drying to obtain a monolith or
powder. The sol–gel chemistry is based on the hydrolysis
and polycondensation of metal alkoxides M(OR)x, where
M = Si, Zr, Ti, Al, etc. and R = any alkyl group. The ﬁrst
reaction is a hydrolysis, which induces the substitution of
OR groups linked to M by M–OH groups. As previously,
these chemical species may react together to form M–O–M
bonds, which lead to the formation of metal network. This
phase establishes a three-dimensional network with solvent
applied in these reactions resting within the pores of the
network. Catauro et al. (35) prepared organic–inorganic
hybrid composite materials via sol–gel process. With PCL
and TiO2 glass serving as organic and inorganic phases, the
drug was added during the sol–gel process. A similar
procedure was adapted to prepare composite ﬁlms with
PMMA and silica by Lin et al. (39) and PCL and zirconia
by Catauro et al. (36). However, the sol–gel reactions are
affected by many parameters, such as structure and
concentration of the reactants, solvents, and catalysts,
reaction temperature, rate of removal of solvents, and the
drug release rate by content of inorganics and coupling
agent (36,39). The process is slow and involves usage of
toxic chemicals.
Fused Deposition
Fused deposition represents a rapid prototyping process
that can make custom speciﬁc structures. Fused deposition
permits one to design and fabricate scaffolds with a com-
pletely interconnected pore network, highly regular and
reproducible scaffold morphology, a microstructure that can
be varied across the scaffold matrix, and a solvent-free
process (67). Fused ingredients are delivered through a
moving nozzle on a moving platform. A suitable computer
program (CAD/CAM design or.stl ﬁle) that decides the
composition of ingredients, degree of fusing, and the design
of the ﬁnal structure of the required implant dictates the
movement of nozzle and platform. As the process involves
fusing, this technique might not be possible for loading the
drugs in matrix with basic components that make the
composite. However, being a solvent-free process, the ill
effects of residual solvents that could affect the stability of
growth factors get shoved away. Rai et al. (22) prepared PCL-
TCP scaffolds by fused deposition modeling with a porosity of
65%. Scaffolds were soaked in PBS for 3 h at 37°C before
rhBMP seeding. Drug loading was performed by adding
the drug to ﬁbrin and then loading it to the scaffold. On
comparison of polymeric and organic–inorganic composite
scaffolds, the authors reported that composites exhibited
comparatively lesser drug loading and higher drug release
on day 1. These results relate to the property of TCP. The
presence of TCP improves hydrophillicity, causing more
dissolution medium penetration and faster diffusion of
drug.
Sponge Reticulate Method
Methods to prepare porous ceramics can be divided into
two groups based on pore structure: One is a foam structure
in which closed pores are dispersed in the matrix; the other is
a reticulate structure, in which open pores are interconnected
through channels (68). A reticulate structure is obtained by
ﬁlling a sponge with slurry of the material and subjecting
them to higher temperatures to burnout the sponge, resulting
in a porous dense ceramic block. Once an inorganic porous
block is obtained, organic polymers can be ﬁlled into pores to
form composites (29,69).
Tampieri et al. reported preparing composites with a
porous Hap skeleton and gelatin ﬁlling mass (69). Porous
inorganic skeleton was prepared by soaking cellulose
sponges with slurry of Hap and sintering at 1,250°C. The
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sintered bodies were immersed in gelatin solution, and a
slow suction under vacuum was applied to coat and ﬁll the
porous structures. They were then air-dried and treated
with glutaraldehyde to cross-link gelatin. Kim et al. (29)
followed a similar technique with some modiﬁcations. With
polyurethane sponge instead of cellulose sponge to form
porous Hap structures, the ﬁlling and coating material
applied was a composite. Porous structures were dipped in
drug containing composite solution made of PCL and Hap
in dichloromethane. Coating a porous drug-loaded inor-
ganic structure with a polymeric solution could be very
pleasing to control drug release. However, the same
polymeric coating may result as an obstacle for new bone
formation and bone in-growth. Pore morphology (pore
connectivity and percent porosity) and pore size play
critical role in rendering Hap ceramics osteoconductivity
and osteoinductivity (70,71). Coating such structures with
polymer locks the micropores and reduces the size of
macropores for a period of time, as governed by the
polymers degradation, affecting the structures’ osteocon-
ductivity. A coating by glycerol-L-lactide on porous Hap
structure (Fig. 2) caused signiﬁcant delay in bone in-growth
as compared to uncoated structures (72).
PROPERTIES
Mechanical Properties
For a successful bone grafting, bone substitutes are
expected to mimic the mechanical properties of the surround-
ing bone. Higher values shall render the surrounding bone
weak, and lower values shall provide ineffective support,
leading to chances of further damage. The average compres-
sive strength and torsion strength of bone ranges from 167 to
145 MPa and 57 to 49 MPa, respectively, depending on age
(73). Causa et al. (23) reported that the elastic modulus of
PCL increased from 8.25 to 27.9 MPa by the addition of Hap,
and the compressive strength and compressive modulus of
organic (PDLLA) scaffolds doubled by the addition of
inorganics biphasic calcium phosphate resulting as compo-
sites. It is obvious that, in a composite, the mechanical
property of one component shall inﬂuence that of the other,
and the addition of drugs is no exception. Negative effects of
drugs on mechanical properties of cement have been reported
(74). Addition of drug to calcium phosphate bone cements
shall inﬂuence the latter’s setting time and compressive
strength. However, by moving to an organic–inorganic
composite, neither the setting time nor compressive strength
is altered signiﬁcantly. Schnieders et al. (24) reported that
addition of gentamicin crobefate to calcium phosphate
cement abolished cement setting, and gentamicin sulfate
addition increased the setting time up to 26 min against the
acceptable limit of 12–15 min. In contrast, there was no or
acceptable change of setting time when the drug-loaded
PLGA microspheres were added to the cement resulting in
a PLGA/calcium phosphate cement composite possibly due
to PLGA acting as a barrier between the drug and cement. In
addition, the compressive strength of calcium phosphate
cement increased signiﬁcantly up to 70 MPa from 52 MPa
by the addition of PLGA microspheres containing drug. Kim
et al. (29) reported that composites fabricated by coating can
improve its mechanical properties signiﬁcantly. Pure Hap
porous scaffolds were compared with those coated with a
mixture of Hap and PCL-containing drug. They reported
that, as compared to pure Hap, coated samples exhibited
higher compressive strength and elastic modulus, with little
inﬂuence from coating composition ratios. These studies
suggest that formation of a composite shall inﬂuence the
mechanical features as compressive strength, compressive
modulus, elastic modulus, and setting time. On the other
hand, they also provide opportunities for tailoring the
properties of the resultant composite by controlling the
processing ingredients as well as the fabrication or processing
parameters. Custom-speciﬁc implant fabrication is also possi-
ble using these inorganic–organic composites.
Drug Release
The release of drug from a carrier system depends on
several factors. Primarily, it would be the area of exposure
and dissolution pattern if the drug was present in a matrix as
with polymers and the type of complex or bond it forms if
present adsorbed on the surface as with glass and ceramics. In
case of composites, the presence of one component shall also
Fig. 2. The basic fuchsin histology of polymer-coated ceramic implants
subjected to in vivo studies. a Polymer (asterisk) ﬁlling the Hap pores
(white arrows) of the composite (black arrows) and acting as barrier for
osteoblasts, resulting in no bone in-growth after 42 days. b Fluorescence-
stained pores (white arrows) were opened after polymer degradation,
and new bone formation and bone in-growth (circle) has happened after
84 days (72) (Reproduced with permission)
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inﬂuence the property of another on drug release. As such a
case, Tuzuner et al. (21) reported that teicoplanin release
from CS-Versa Bond™ composite was better when compared
to its release from Versa Bond™ alone. In another case, a β-
TCP, calcium phosphate invert glass, chitosan composite
exhibited a better gentamicin release proﬁle than a chitosan
matrix (30). The addition of β-TCP and calcium phosphate
invert glass to a chitosan matrix greatly reduced the burst
release of gentamicin followed by a higher and steadier
release proﬁle. While the dissolution of β-TCP and calcium
phosphate invert glass increased the phosphate concentration
in the dissolution medium that improved the cross-linking of
chitosan, calcium and sodium ions restricted the enhanced
dissolution of chitosan acetate by buffering the local dis-
solution medium, thereby restricting the release of gentami-
cin. In addition, the apatite-forming ability of a composite
shall also inﬂuence drug release. It has been reported that
apatite formation sustained the release of drug by about
threefold in simulated body ﬂuid (SBF) (27). Another
signiﬁcant advantage that a composite may offer for drug
delivery is linear release kinetics (24,31). Schnieders et al.
reported that the release of gentamicin crobefate from a
PLGA microsphere/calcium phosphate cement composite
followed a nearly zero-order kinetic, which was characterized
by a slower but linear release over 100 days without initial
drug burst against triphasic drug release kinetic from PLGA
microsphere or plain drug-loaded bone cement (24). A
sustained release from PLGA microspheres followed possibly
by adsorption of the released drug on calcium phosphate
cement matrix, and slower drug diffusion out of it resulted to
a linear drug release proﬁle. In addition to a stable in vitro
release, it is also mandatory to know whether the released
drug for prolonged period retains its antimicrobial property.
Makinen et al. (26) reported that the antibacterial activity of
released ciproﬂoxacin from composite, after manufacturing
and sterilization processes, was similar to the non-processed
ciproﬂoxacin throughout the process of release. Finally, in a
conventional sustained release therapy, there shall exist
a slow residual release with suboptimal concentrations. Such
a release shall not be a point of discussion with most classes of
drugs, however, not with antibiotics, as suboptimal release of
antibiotics might cause chances for development of drug
resistance in microorganisms. However, Makinen et al. (26)
reported that, with composites, the release proﬁle appeared
safer, avoiding worries related with drug resistance.
Many studies have reported the kinetics and mechanism
of drug release from various composite systems. It appears
that the drug release mechanism from a composite is not
simple diffusion alone, and it gets inﬂuenced by various other
factors, such as ion exchange between composite and SBF,
formation of bioactive component (apatite) on the surface of
composite, and or dissociation of drug from the complex
formed with the component of composite (18,27,32,33).
Researchers (27,32,33) observed that the fraction of the drug
released from a heterogeneous parallelepiped-shaped, insolu-
ble (partially in these cases), porous composite versus square
root of time ﬁtted to a third order polynomial and the value
of release rate constant (Kb) could be obtained by
applying the experimental values in the following equation
ft ¼ a0b0þa0c0þb0c0ð ÞV0 Kbt1=2 
a0þb0þc0ð Þ
V0
K2bt þ 1V0 K3bt3=2 where ft is
the fraction of drug released at time (t), Kb the boundary
retreat rate constant, a0, b0, and c0 the parallelepiped
dimensions, and V0 the parallelepiped volume. With reduced
burst release, higher and sustained release with linear drug
release kinetics organic–inorganic composites exhibit desirable
drug release proﬁles suitable for local drug delivery in bone.
The drug release proﬁle can be theoretically modeled and can
be of great help in the design of drug-releasing scaffolds
applied for the treatment of certain chronic diseases like
osteomyelitis, where controlled local delivery of drug is
required for a relatively longer period.
Biocompatibility
Although biologically acceptable ingredients are present
in the ﬁnal form of composite, a problem of bio non-
compatibility could arise due to the presence of trace
amounts of solvents, monomers released from polymers, or
due to processing factors. The biocompatibilities of composite
scaffolds are studied by in vitro cell culture method by
employing osteoblast-like human osteosarcoma cell lines as
MG63. The cell growth on the surface and migration into
pores of the composite, if any, and their morphology and
attachment all indicate biocompatibility and suitability of the
material for in vivo use (30). Cell proliferation is popularly
observed by 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assay (23,28) or ﬂuorescence micro-
graph (23). Zhang et al. observed the inﬂuence of invert
calcium phosphate glass and β-TCP on the biocompatibility
of chitosan scaffolds (30). They observed that MG63 cells
attached and grew with similar morphology on composite
scaffolds and chitosan scaffolds. This indicates that addition
of new (biocompatible) ingredients to a biocompatible
substance need not necessarily inﬂuence the biocompatibility.
However, this study does not mention the composition of the
composite scaffold subjected to the cell culture study, and
hence, its result better dealt with caution.
Zhang et al. (23) employed ROS 17/2.8 rat osteoblastic
cell lines for biocompatibility studies for PDLLA/BCP
composite scaffolds and those coated with PEG and PEG–
vancomycin. Cell proliferation was observed by ﬂuorescence
micrographs and MTT assay. Figure 3 displays the ﬂuores-
cence micrograph of the studied samples on days 1 and 6 (23).
The results showed that cells attached and continue to
proliferate in all samples, indicating that PEG and vancomy-
cin coating had no negative effect, and all three had good
biocompatibility. Alternatively, cell responses to composites
can be assessed with the liquid extracts of composites (28).
Kim et al. (28) studied the biocompatibility of phosphate
glass–PCL-based composites. Two varieties of phosphate
glass were used, which differed on their CaO content, thereby
inﬂuencing the solubility of glasses. MG63 cells proliferated
well on the extracts. When compared to the composite
containing highly dissolvable glass (with lower CaO content),
those with less soluble glass (with higher CaO content)
showed a higher proliferation level. As the pH of extracts
was maintained uniformly, the difference in cell proliferation
could be attributed to inﬂuence of ionic range appropriate for
cellular activity. The biocompatibility studies on composites
are very limited. However, the tested composites have been
reported to be biocompatible (28,30). There is ample scope of
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future research in this area. A study on biocompatibility of
these composites should be considered mandatory than
optional in research.
Bioactivity
The bioactivity of a composite and its individual compo-
nents can be assessed in vitro (32,33,35,36,49) by their ability
to form apatite layer on surface overcoming the possible
interference of polymer and drug if any. In vitro bioactivity
studies are conducted by immersing the samples in SBF,
which have the composition and ionic concentration similar to
human plasma, at 37°C (Fig. 4). As a result of surface
interaction with SBF, a layer of Hap starts to form on the
surface. However, the crystallinity of the apatite phase
formed on the composite surface may be lower than that
formed on the surface of individual bioactive component
during the same period. The formation of apatite can be
analyzed by X-ray diffraction, scanning electron microscopy,
X-ray energy dispersive spectroscopy, and/or with Fourier
transform infrared (32,33). With concern on animal usage in
experimentation, the in vitro method for bioactivity study
gains more appreciation. Standards for in vitro measurement
of apatite-forming abilities on implant materials (ISO/DIS
23317) are in the development stage by the International
Organization for Standardization.
Biodegradation/Bioresorption
Biodegradation is the breakdown of macromolecules by
the action of a living system or via enzymes and thus cells,
and bioresorption is the elimination of byproducts of
biodegradation from an animal organism via natural path-
ways. Biodegradation of drug-releasing composites is studied
Fig. 3. Fluorescent micrograph of the osteoblast cultured on PDLLA/BCP scaffolds without
coating (a, d), with PEG coating (b, e), with PEG–vancomycin coating (c, f). a–c Day 1; d–f day 6
(23) (Reproduced with permission)
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in vitro by observing the decrease in weight of the sample and
molecular weight of the degrading polymer after immersion
in a medium at 37°C for various periods of time with liquids
as sterile pH 7.4 PBS solution (28,29,53,56,75) or SBF (75)
acting as medium for degradation. Although both the liquids
are not very appropriate in simulating the in vivo environ-
ment, SBF is a better choice than PBS. SBF simulates pH and
ionic concentrations more closely as plasma (Fig. 4) and also
imparts bioactivity to the sample in study. Hence, when a
composite is subjected to biodegradation studies, the one in
SBF will also exhibit bioactivity and inﬂuence the degrada-
tion simulating better in vivo condition.
In general, the weight loss of the composite scaffolds is
monitored over a period of time. In addition, studies on
change in molecular weight of the polymer determined by gel
permeation chromatography (28) and the concentration of Ca
and P released from the composites determined by induc-
tively coupled plasma atomic emission spectroscopy (28) do
exist. If the structure is porous, changes in pore morphology
can be observed by SEM. As a result of hydrolytic
degradation, the decrease in weight of the composite could
be monophasic (almost linear weight loss with time) (28),
biphasic (fast initial loss further decreased loss) (28), or
triphasic (fast initial and terminal with decreased intermedi-
ate) (53), depending on the composition of the composite
materials. In the case of composites prepared by coating,
thickness of the coat inﬂuences the degradation as well (29).
Kim et al. observed that the degradation of PCL–
phosphate glass composites was heavily inﬂuenced by varia-
tion of CaO concentrations in a P2O5–CaO–Na2O glass
system, though the organic to inorganic phase ratio remained
constant (28). It was observed that the concentration of CaO
in the glass and the degradation were inversely proportional.
The lower the CaO, the faster is the weight loss, and the
higher the Cao, the slower is the weight loss of the composite.
The composites with high CaO glass exhibited almost linear
weight loss with time, while other compositions showed a fast
initial loss and further decreased rate. Although addition of
glass increased the weight loss of the scaffold, this change in
trend based on CaO concentration could be attributed to the
solubility of the glass, as higher CaO concentrations are
observed to lower the solubility of P2O5–CaO–Na2O glasses
(76,77). However, this study was conducted for only 7 days,
and hence, the degradation of PCL and its inﬂuence in this
degradation cannot be assumed to be substantial. The
inﬂuence of slower degrading polymers can be observed only
when studied for prolonged periods of time.
The composites of Niu et al. made with nano-Hap-
collagen-PLLA exhibited a three-phase weight loss with the
introduction of cross-linked chitosan microspheres and the
weight loss proportional to the chitosan microsphere propor-
tion in the composite (53). Figure 5 depicts the three-phase
weight loss curves of the studied composite with varying
proportions of chitosan microspheres (53). The three-phase
trend is more pronounced with higher proportions (30% and
50%) of chitosan microspheres. The rate of weight loss was
higher during the ﬁrst phase (ﬁrst 3 weeks) and third phase
(14–18 weeks) due to preferential dissolution of chitosan
microspheres and degradation of PLLA, respectively. In the
second phase, the degradation rather slowed down. In
common, the degradation of most synthetic semicrystalline
polymers as PLLA that undergo hydrolytic degradation
exhibits two phases. In the ﬁrst phase, water diffuses into
the polymer that converts the long polymer chains into
shorter ones. As this occurs in the amorphous region, there
is reduction in molecular weight but no loss in physical
properties, while the crystalline regions hold the structure
together. In the second phase, crystalline regions fragment
and the related physical properties diminish with the frag-
ments metabolized in vivo by enzymes, resulting in a rapid
loss of polymer mass (78). Hence, it could be concluded that
the period for in vitro studies on biodegradation or biore-
sorption be decided based on the components of the
composite studied and not arbitrarily.
IN VIVO ASSESSMENT
In vivo assessment of a composite is not just restricted to
drug release but extended to its bioactivity. In vivo studies are
carried out in rabbits following radical debridment of
localized osteomyelitis and drug concentrations estimated by
extracting the drug from bone specimens (26). Generally, the
Fig. 4. Schematic depiction of in vitro bioactivity test based on
dynamic protocol and ionic composition of SBF in comparison with
human plasma
Fig. 5. Weight loss of nano-Hap-PLLA-Chitosan microspheres scaf-
folds with different chitosan microspheres contents during hydrolytic
degradation (53) (Reproduced with permission)
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drug concentration was high in and around the areas in which
the composites were in contact, and the concentration
decreased as the distance increased. Therefore, under clinical
conditions of use, there could be an obvious need for systemic
administration of drugs to protect the surrounding bones and
tissues, at least for a limited period initially. Otherwise,
composites appear suitable enough in releasing the drugs
and in their active form throughout the study period (26).
However, it is not a case unique to composites, and similar
conditions are exhibited by drug delivery systems either
prepared by the polymer or inorganic. In vivo biodegradation
and concomitant new bone formation can be studied by
means of sequential peripheral quantitative computed tomog-
raphy imaging of the density and area of trabecular and
cortical bone. The decrease in cortical bone area as a function
of time with a concurrent increase in its density is an
indication of bone remodeling response. Miyai et al. (20)
reported the new bone formation and osteoconduction of
composites. After 50 weeks of study in rabbit, the composites
were surrounded by mature bone. In-growth of thin bone
tissues was also observed along the inner wall of the pores of
the ceramic, which indicated degradation of the polymer and/
or ceramic at the ceramic/polymer interface and subsequent
replacement by the thin bone tissues. In some pores, bone
tissue with vascular channels was also formed. These studies
assure the ability of the composites in delivering drug locally
and biointeraction with local tissue, leading to new bone
formation. However, due to ethical issues, experimental
design, and biological and study conditions, in vivo results
may be highly inﬂuenced by statistics, and in the case of
organic–inorganic composites, the reports are relatively few.
CONCLUSION
Application of individual components such as polymer or
ceramic for bone ﬁlling and drug release is in practice for a
couple of decades. In addition, the idea of application of a
composite in the same area is picking up faster. With reports
assuring the ability of composites to deliver drug and favor
new bone formation with acceptable mechanical properties
and biocompatibility, composites have a major role in tissue
engineering and drug delivery for bone. However, there are
still many questions to be answered. Not all composites
behave in the same manner and not two compositions of the
same composite in releasing drug. In addition, the manufac-
turing technique also plays its role. Properties like drug
delivery and biodegradation are the ﬁrst that shall get
affected by this, and interestingly, they are the key determi-
nants that take a particular composite in or outside the
acceptable boundary. If all the initial hurdles were crossed,
the ﬁnal would be industrialization and commercialization.
From a tissue engineering perspective, selection of a method
that provides the best mechanical strength to the ﬁnal unit
would be more important. However, from a pharmaceutical
perspective, the conditions like temperature and pressure that
may favor drug decomposition shall restrict the selection.
Newer techniques as rapid prototyping would help to make
structures that have the best uniformity and reproducibility as
far as even distribution of drug and porosity are considered.
Nevertheless, mechanical ability of those structures to com-
pete with structures made by compression as Iso Static Press
is to be considered. At present, the market segment for these
kinds of systems is relatively small worldwide. Hence, at the
present juncture, it would be better to form composite
structures that are more suitable in space ﬁlling and new
bone formation, with provisions for drug incorporation at
later stages. The drug choice can be left to the surgeon who
could incorporate the drug into composite prior to surgery as
the case desires. Such a path would provide a broader market
potential than a single drug ﬁxed dose composition in a
composite.
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